08:00 , Nov 13, 2014 |  BC Innovations  |  Cover Story

Boosting adjuvants

For all the talk of new vaccines, not much attention has been paid to the need for better adjuvants, which have remained stuck on alum-based products for decades. The NIH is committing up to $70...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

NanoBio, Merck deal

NanoBio granted Merck exclusive, worldwide rights to NanoBio's nanoemulsion-based adjuvant technology for use in an intranasal respiratory syncytial virus (RSV) vaccine and non-exclusive, worldwide rights for use in an intranasal seasonal influenza and/or universal seasonal...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Financial News

NanoBio completes venture financing

NanoBio Corp. , Ann Arbor, Mich.   Business: Infectious   Date completed: 11/28/12   Type: Venture financing   Raised: $11 million   Investors: Existing investors  ...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Company News

NanoBio, Health Protection Agency (HPA), NIH infectious, drug delivery news

NIH's National Institute of Allergy and Infectious Disease (NIAID) awarded HPA a two year, £4 million ($6.4 million) contract to develop a next-generation anthrax vaccine . HPA will use NanoBio's NanoStat adjuvant technology to enable...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

NanoBio management update

NanoBio Corp. , Ann Arbor, Mich.   Business: Infectious   Departed: Co-founder and CEO James Baker, while remaining a director, to become SVP of head global vaccine franchise at Merck & Co. Inc. ; he...
01:18 , Oct 10, 2012 |  BC Extra  |  Company News

NanoBio CEO leaves to head Merck vaccine franchise

NanoBio Corp. (Ann Arbor, Mich.) said founder and CEO James Baker left to join Merck & Co. Inc. (NYSE:MRK) as SVP, head global vaccine franchise. NanoBio promoted David Peralta to CEO from COO and CFO....
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

NanoBio, Merck deal

The partners will evaluate combining Merck's respiratory syncytial virus (RSV) antigen and NanoBio's NanoStat adjuvant technology for use as an intranasal vaccine. Merck has an option to license non-exclusive rights to NanoBio's NanoStat adjuvant technology...
07:00 , Sep 5, 2011 |  BC Week In Review  |  Clinical News

NanoBio preclinical data

In mice, vaccination with NanoBio's intranasal nanoemulsion-adjuvanted inactivated respiratory syncytial virus (RSV) vaccine significantly increased levels of RSV-specific immunoglobulin A (IgA) , IgG2a and IgG1 antibodies at week 8 vs. unvaccinated mice (p<0.01 for all),...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Company News

NanoBio deal

NanoBio received exclusive, worldwide rights from NIH to an antigen against respiratory syncytial virus (RSV). NanoBio said it will combine its NanoStat adjuvant technology with the antigen for use in the company's RSV vaccine ....
07:00 , Jul 4, 2011 |  BC Week In Review  |  Clinical News

Nanoemulsion-adjuvanted influenza vaccine: Phase Ib started

NanoBio began a single-blind Phase Ib trial in about 125 healthy volunteers to compare NB-1008 via a sprayer device and a pipette dropper vs. Fluzone from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France). NanoBio Corp. , Ann...